An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab (Avastin)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms ASCENT
Sponsors Roche

20 Jan 2018 Primary endpoint (Neutrophil to Lymphocyte Ratio (NLR) for an Association With PFS) has not been met, according to results presented at the 2018 Gastrointestinal Cancers Symposium.
20 Jan 2018 Results assessing the prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab, presented at the 2018 Gastrointestinal Cancers Symposium.
01 Nov 2016 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com